Ausztrália - angol - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - cephalexin as cephalexin monohydrate - oral tablet - cephalexin as cephalexin monohydrate antibiotic active 300.0 mg/tb - antibiotic & related - dog | bitch | castrate | puppy - enterobacter spp. | escherichia coli (e. coli) | infections of soft cutaneous tissue | infections of the digestive tract | infections of the respiratory tract | infections of the urinary tracts | klebsiella spp. | osteomyelitis | proteus spp. | salmonella | shigella spp. | staphylococcus aureus | acute respiratory infections | bronchiseptica | bronchitis | escherichia coli | group d streptococcus | including b-lactamase producin | klebsiella spp. | pharyngitis | pneumonia | proteus spp. | pseudomonas aeruginosa | salmonellosis | staphylococcus spp. | tonsillitis

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - cefalexin monohydrate -

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - cefalexin monohydrate -

Egyesült Államok - angol - NLM (National Library of Medicine)

tya pharmaceuticals - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg - cephalexin capsules usp are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by and . (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) streptococcus pneumoniae streptococcus pyogenes otitis media due to , , , , and . streptococcus pneumoniae haemophilus influenzae staphylococcus aureus streptococcus pyogenes moraxella catarrhalis skin and skin structure infections caused by and/or . staphylococcus aureus streptococcus pyogenes bone infections caused by and/or .

Egyesült Államok - angol - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - 1 indications and usage 1.1 respiratory tract infections cephalexin capsules usp are indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes. 1.2 otitis media cephalexin capsules usp are indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae, haemophilus influenzae, staphylococcus aureus, streptococcus pyogenes, and moraxella catarrhalis. 1.3 skin and skin structure infections cephalexin capsules usp are indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes. 1.4 bone infections cephalexin capsules usp are indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis. 1.5 genitourinary tract infections cephalexin capsules usp are indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli, proteus mirabilis, and klebsiella pneumoniae. 1.6 usage to reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules usp and other antibacterial drugs, cephalexin capsules usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information is available, this information should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cephalexin capsules are contraindicated in patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs. 8.1 pregnancy risk summary available data from published epidemiologic studies and pharmacovigilance case reports over several decades with cephalosporin use, including cephalexin use in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data). animal reproduction studies with mice and rats using oral doses of cephalexin that are 0.6- and 1.2-times the maximum recommended human dose (mrhd) based on body surface area during organogenesis revealed no evidence of harm to the fetus (see data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data human data: while available studies cannot definitively establish the absence of risk, published data from epidemiologic studies and postmarketing case reports over several decades have not identified a consistent association with cephalosporin use, including cephalexin, during pregnancy, and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups. animal data: in animal reproduction studies, pregnant mice and rats administered oral cephalexin doses of 250 or 500 mg/kg/day (approximately 0.6 and 1.2 times the mrhd) based on body surface area, respectively during the period of organogenesis showed no adverse effects on embryofetal development. in a pre-and post-natal developmental toxicity study, pregnant rats that received oral doses of 250 or 500 mg/kg/day of cephalexin from day 15 of pregnancy to litter day 21 showed no adverse effects on parturition, litter size, or growth of offspring. 8.2 lactation risk summary data from a published clinical lactation study reports that cephalexin is present in human milk. the relative infant dose (rid) is considered to be <1% of the maternal weight adjusted dose. there are no data on the effects of cephalexin on the breastfed child or on milk production. the development of health benefits of breastfeeding should be considered along with the mother's clinical need for cephalexin and any potential adverse effects on the breastfed child from cephalexin or from the underlying maternal condition. 8.4 pediatric use the safety and effectiveness of cephalexin capsules in pediatric patients was established in clinical trials for the dosages described in the dosage and administration section [see dosage and administration (2.2)] 8.5 geriatric use of the 701 subjects in 3 published clinical studies of cephalexin, 433 (62%) were 65 and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. this drug is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection [see warnings and precautions (5.4)]. 8.6 renal impairment cephalexin capsules should be administered with careful monitoring in the presence of renal impairment (creatinine clearance < 30 ml/min, with or without dialysis). under such conditions, careful clinical observation and laboratory studies renal function monitoring should be conducted because safe dosage may be lower than that usually recommended [see dosage and administration (2.3)].monitor patients longer for toxicity and drug interactions due to delayed clearance.

Egyesült Államok - angol - NLM (National Library of Medicine)

a-s medication solutions - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg in 5 ml - cephalexin is indicated for the treatment of respiratory tract infections caused by susceptible isolates of streptococcus pneumoniae and streptococcus pyogenes. cephalexin is indicated for the treatment of otitis media caused by susceptible isolates of streptococcus pneumoniae , haemophilus influenzae , staphylococcus aureus , streptococcus pyogenes , and moraxella catarrhalis. cephalexin is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following gram-positive bacteria: staphylococcus aureus and streptococcus pyogenes . cephalexin is indicated for the treatment of bone infections caused by susceptible isolates of staphylococcus aureus and proteus mirabilis. cephalexin is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of escherichia coli , proteus mirabilis , and klebsiella pneumoniae . to reduce the development of drug-resistant bacteria and maintain the effectiveness of cep

Egyesült Államok - angol - NLM (National Library of Medicine)

northwind pharmaceuticals - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 500 mg - cephalexin capsules usp are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes. (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae, haemophilus influenzae, staphylococcus aureus, streptococcus pyogenes, and moraxella catarrhalis. skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes. bone infections caused by staphylococcus aureus and/or proteus mirabilis. genitourinary tract infections, including acute prostatitis, caused by escherich

Kenya - angol - Pharmacy and Poisons Board

cephalexin - capsule - cephalexin 250mg - cefalexin

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin monohydrate -

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin monohydrate -